Professor Bhupinder Singh Bhoop, a global pioneer in the development of novel and nano-structured drug delivery using Formulation by Design (FbD), i.e., a QbD-based paradigm, was bestowed with “Outstanding Scientist Award” for his contribution  in the domain of pharmaceutical sciences and research.

The award was presented to him during an international conference on “Quality by Design (QbD): Excellence and Compliance” in pharmaceutical manufacturing, organized by Select Bio (UK) in Mumbai recently. This award is a sequel to numerous other national, global awards and accolades already conferred on him.

The award was presented by Dr Brain Carlin, director, FMC Corporation, New York, USA; Dr Adnan Sabir, vice president, Kowa Pharma Inc., California, USA, and Dr Sushil Srivastava, director, Bristol Myers Squib, New York, USA.

Prof. Bhoop has to his credit more than 200 publications, 33 book chapters, nine books, four patents, nearly 220 conference presentations including 24 best paper awards and key involvement in the tech. transfer of two nano-based drug delivery products for serving the ailing patients. He has trained several hundreds of industrial scientists under his guidance, especially on QbD via conferences, onsite training seminars and workshops.

Presently working as a Professor at University Institute of Pharmaceutical Sciences, Panjab University, Prof. Bhoop is also the co-ordinator, UGC Centre of Advanced Studies (CAS) in Pharma Sciences, and founder co-ordinator of UGC Centre of Excellence in Nano Applications (Biomedical Sciences) at Panjab University. He also served as the dean, Faculty of Pharmaceutical Sciences, Panjab University, from 2012-2014, and as dean, Alumni Relations, Panjab University, from 2007-2011. He is currently a Fellow and a sitting member of the Panjab University Syndicate too.

QbD is buzzword in pharma industry today. It is a new science- and risk-based approach for developing pharmaceutical formulations leading to comprehensive understanding of the product(s) and process(es) to avoid quality crisis in the final product. As per the recent US-Food Drug Administration (FDA) directives, no generic drug products can enter into the US market after January 1, 2013 without complying with the QbD standards.

Prof. Bhoop was invited as the keynote speaker at the conference to deliver talk on QbD applications during various stages of pharma product development lifecycle. Besides him, a score of other eminent speakers from industry and academia across the globe including from, USA, UK, Canada, France, Singapore, Germany, Mexico and India also deliberated during the two day international conference.

Select Bio is a premier professional and scientific organization of UK origin. Besides UK, it has various other offices worldwide including in USA, Canada, Singapore and India. Of late, Select Bio - India has undertaken dedicated initiatives by organizing conferences on emerging paradigms in pharma and biotechnology to cater to the emerging demands of industry.